Clinical effectiveness of Longjin Tonglin capsule in the treatment of chronic prostatitis combined with semen abnormalities

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300068600

Enrollment

Unknown

Registered

2023-02-24

Start date

2022-03-01

Completion date

Unknown

Last updated

2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic prostatitis combined with semen abnormalities

Interventions

experience group:Longjin Tonglin Capsule

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria 1 Meeting the diagnostic criteria for type III chronic prostatitis. 2 Meet the diagnostic criteria for semen abnormalities. 3 Meet the diagnostic criteria of "damp-heat stasis evidence" in Chinese medicine. 4 18 years old = age = 50 years old. 5 Duration of disease = 3 months. 6 Understand, agree to participate in this trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria 1 Other diseases that lead to abnormal semen except for chronic prostatitis such as special pathogen infection, varicocele, testicular, endocrine, immune and idiopathic diseases; 2. Urinary tract infection, hematospermia, prostate cancer, neurogenic bladder, urethral malformation or stricture, and severe neurosis; 3. Ureteral calculus, bladder calculus, inguinal hernia, pubitis, varicocele, epididymitis, rectocolic disease, lumbodorsal myofascitis; 4. Patients with severe cardiac, cerebrovascular, liver and kidney damage or serious diseases of respiratory system, digestive system, hematopoietic system and mental diseases; 5 Those who are allergic to the drug ingredients or excipients in this study, or those with severe allergic constitution; 6 Have taken similar drugs within 3 months; 7 Those who have participated or are participating in other clinical trials three months ago; 8 The researcher assessed that it was not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
NIH-CPSI score;Prostate fluid;TCM symptom severity points;	—

Secondary

Measure	Time frame
Semen analysis;	—

Countries

China

Contacts

Public ContactYu Peng

Yueyang Hospital of Integrated Traditional Chinese and Wesitern Medicine, Shanghai University of Traditional Chinese Medicine

drypeng@sina.com+86 18930568233

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026